Cencora (COR) vs Nu Skin Enterprises (NUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cencora (COR) has outperformed Nu Skin Enterprises (NUS) over the past year, gaining 2.8% versus a loss of 56.8%. Over five years, COR leads with a +164.7% price change compared with -88.3% for NUS. Cencora is the larger company by market cap ($60.54 billion vs $233.6 million), about 259.1 times the size.
On valuation, Nu Skin Enterprises trades at a lower forward P/E (4.1x vs 16.0x for Cencora). Nu Skin Enterprises offers the higher dividend yield (5.00% vs 0.74%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COR | NUS |
|---|---|---|
| Share price | $317.25 | $4.80 |
| Market cap | $60.54B | $233.65M |
| 1-day change | +0.28% | +1.27% |
| YTD return | -6.07% | -50.10% |
| 1-year return | +2.77% | -56.80% |
| 5-year return | +164.68% | -88.30% |
| P/E ratio (TTM) | 23.55 | — |
| Forward P/E | 16.02 | 4.14 |
| EPS (TTM) | $13.47 | $-4.57 |
| Dividend yield | 0.74% | 5.00% |
| Annual dividend | $2.35 | $0.24 |
| Revenue (latest FY) | $321.33B | — |
| Revenue growth (YoY) | +9.31% | — |
| Net income (latest FY) | $1.55B | — |
| Gross margin | 3.57% | — |
| Operating margin | 0.82% | — |
| Net margin | 0.48% | — |
| 52-week high | $377.54 | $11.67 |
| 52-week low | $244.82 | $4.45 |
| Distance from 52-week high | -15.97% | -58.87% |
| Analyst consensus | buy | — |
| Avg. price target upside | +16.39% | — |
| Average volume | 1.34M | 556.99K |
| Shares outstanding | 190.83M | 48.68M |
| Employees | 47,000 | — |
| Sector | Health Care | Health Care |
| Industry | Other Pharmaceuticals | Other Pharmaceuticals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cencora is about 259.1 times larger than Nu Skin Enterprises by market value ($60.54B vs $233.65M).
- COR has outperformed NUS by 59.6 percentage points over the past year.
- Nu Skin Enterprises offers a meaningfully higher dividend yield (5.00% vs 0.74%).
About Cencora
COR stock →Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
Health Care · Other Pharmaceuticals · 47,000 employees
COR vs NUS FAQ
Which is bigger, Cencora or Nu Skin Enterprises?
Cencora (COR) is larger, with a market capitalization of $60.54B compared with $233.65M for Nu Skin Enterprises (NUS).
Which stock has performed better over the past year, COR or NUS?
COR returned +2.77% over the past 12 months, compared with -56.80% for NUS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cencora or Nu Skin Enterprises?
Nu Skin Enterprises has the higher yield at 5.00%, compared with 0.74% for Cencora.
Are Cencora and Nu Skin Enterprises in the same industry?
Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.